Tabula Rasa Healthcare (TRHC) On Track For 20% Organic Growth - Baird

Baird analyst Matthew Gillmor reiterated an Outperform rating and $90.00 price target on Tabula Rasa Healthcare (NASDAQ: TRHC) after CMS data for March indicated national PACE enrollment increased by 8.5% y/y.

The analyst stated "March enrollment data is mostly consistent with recent growth trends, which averaged 8-10% in monthly enrollment gains from 2015-2019. In our view, this should support TRHC's >20% organic growth outlook, after considering faster growth with TRHC's PACE clients, market share opportunities within PACE, as well as TRHC's emerging offerings for payers, providers, and pharmacy organizations".

For an analyst ratings summary and ratings history on Tabula Rasa Healthcare click here. For more ratings news on Tabula Rasa Healthcare click here.

Shares of Tabula Rasa Healthcare closed at $60.31 yesterday.

You May Also Be Interested In

• BofA Securities Upgrades Etsy (ETSY) to Buy, 'Still Room to Run'
• Lowe's (LOW) PT Lowered to $260 at Barclays
• Marvell (MRVL) PT Raised to $310 at UBS